MOLECULERA BIOSCIENCES Trademark
Trademark Overview
On Tuesday, April 30, 2024, a trademark application was filed for MOLECULERA BIOSCIENCES with the United States Patent and Trademark Office. The USPTO has given the MOLECULERA BIOSCIENCES trademark a serial number of 98526774. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, November 19, 2024. This trademark is owned by Moleculera Biosciences, Inc.. The MOLECULERA BIOSCIENCES trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:
Antibody testing for medical diagnostic or treatment purposes; Blood testing being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Blood testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Blood serum testing being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Blood serum testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Immunochemical medical diagnostic testing services for detecting and measuring antibody levels; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical diagnostic services; Medical diagnostic testing, monitoring and reporting services; Medical testing for diagnostic or treatment purposes
Laboratory testing of materials; Medical and scientific research in the field of autoimmune neuropsychiatric disorders, and other immune mediated disorders, such as cardiovascular, long-covid, and cognitive disorders, symptoms, testing, and treatment; Medical research laboratory services; Providing a website featuring educational information in the field of clinical research; Providing information about medical research in the field of autoimmune neuropsychiatric disorders, and other immune mediated disorders, such as cardiovascular, long-covid, and cognitive disorders, symptoms, testing, and treatment; Research laboratory analysis services in the field of autoimmune neuropsychiatric disorders, and other immune mediated disorders, such as cardiovascular, long-covid, and cognitive disorders, symptoms, testing, and treatment
General Information
| Serial Number | 98526774 |
| Word Mark | MOLECULERA BIOSCIENCES |
| Filing Date | Tuesday, April 30, 2024 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Tuesday, November 19, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Antibody testing for medical diagnostic or treatment purposes; Blood testing being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Blood testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Blood serum testing being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Blood serum testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Immunochemical medical diagnostic testing services for detecting and measuring antibody levels; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical diagnostic services; Medical diagnostic testing, monitoring and reporting services; Medical testing for diagnostic or treatment purposes |
| Goods and Services | Laboratory testing of materials; Medical and scientific research in the field of autoimmune neuropsychiatric disorders, and other immune mediated disorders, such as cardiovascular, long-covid, and cognitive disorders, symptoms, testing, and treatment; Medical research laboratory services; Providing a website featuring educational information in the field of clinical research; Providing information about medical research in the field of autoimmune neuropsychiatric disorders, and other immune mediated disorders, such as cardiovascular, long-covid, and cognitive disorders, symptoms, testing, and treatment; Research laboratory analysis services in the field of autoimmune neuropsychiatric disorders, and other immune mediated disorders, such as cardiovascular, long-covid, and cognitive disorders, symptoms, testing, and treatment |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 30, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | Thursday, February 22, 2024 |
| First Use In Commerce Date | Thursday, February 22, 2024 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 30, 2024 |
| Primary Code | 044 |
| First Use Anywhere Date | Thursday, February 22, 2024 |
| First Use In Commerce Date | Thursday, February 22, 2024 |
Trademark Owner History
| Party Name | Moleculera Biosciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Oklahoma City, OK 73104 |
Trademark Events
| Event Date | Event Description |
| Tuesday, April 30, 2024 | NEW APPLICATION ENTERED |
| Wednesday, October 16, 2024 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Wednesday, October 16, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, October 16, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, October 16, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, October 23, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, November 14, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, November 19, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, November 19, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, November 19, 2024 | NON-FINAL ACTION WRITTEN |
